World Journal of Endocrine Surgery

Register      Login

VOLUME 2 , ISSUE 3 ( September-December, 2010 ) > List of Articles


A Systematic Review and Analysis of Reporting Quality of Studies of Germline Genetic Variants Influencing Susceptibility to Nonmedullary Thyroid Cancer

Judith E Ritchie, Sabapathy P Balasubramanian

Citation Information : Ritchie JE, Balasubramanian SP. A Systematic Review and Analysis of Reporting Quality of Studies of Germline Genetic Variants Influencing Susceptibility to Nonmedullary Thyroid Cancer. World J Endoc Surg 2010; 2 (3):119-126.

DOI: 10.5005/jp-journals-10002-1035

Published Online: 01-08-2013

Copyright Statement:  Copyright © 2010; The Author(s).



A systematic review of the existing literature was carried out, identifying studies through a search of the Medline literature via PubMed and through scanning of references of these papers. These papers were then subject to an assessment of quality of reporting using a scoring system modified from previously published criteria.


50 studies published between 1997 and 2010 were included. These studies included 916 polymorphisms across 62 genes involved in a diverse range of cellular processes using 10,704 cases and 27,707 controls. The median quality score was 70.4% (range 52-93%). Areas of strength and weaknesses in study reporting were identified.


Research on the genetic susceptibility to nonmedullary thyroid cancer is sparse. Published studies are of suboptimal quality, have analyzed few variants and positive findings have not been replicated. Adherence to recently published guidelines on methodology should be encouraged. A consortium led approach involving multiple centers, including large numbers of patients in well-defined study protocols is required to investigate this subject comprehensively.

PDF Share
  1. “Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer.” Lancet Oncology 2009;10(2):181-90.
  2. “Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma.” Endocrine-Related Cancer 2009;16:491-503.
  3. “Extended Structural Variation of a Pentonucleotide Repeat in the GSTP1 gene: Characterisation in a Normal Population and in Thyroid and Gastric Tumours” European J Human Genet 2000;8:540-44.
  4. “Thyroid cancer susceptibility and THRA1 and BAT-40 repeats polymorphisms.” Cancer Epidemiol Biomarkers Prev 2005;14(3):638-42.
  5. “Strong association of chromosome 1p12 loci with thyroid cancer susceptibility.” Cancer Epidemiol Biomarkers Prev 2008;17(6):1499-1504.
  6. “Thyroid papillary carcinoma: Preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene.” J Endocrinol 2004;182(3):479-84.
  7. “Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer.” Exp Dermatol 2009;18(6):548-552.
  8. “Smoking and susceptibility to thyroid cancer: An inverse association with CYP1A1 allelic variants.” Endocrinol Related Cancer 2006;13(4):1185-93.
  9. “Size matters: Just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology.” Int J Epidemiol 2009;38(1):263-273.
  10. “Higher glutathione transferase GSTM1 0/0 genotype frequency in young thyroid carcinoma patients.” Curr Med Res Opinion 2003;19(2):102-06.
  11. “Cancer Research UK Cancer Statistics 2010.”
  12. “Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma.” Clin Cancer Res 2008;14(8):5919-24.
  13. “A systematic review of the quality of genetic association studies in human sepsis.” Intensive Care Medicine 2006;32(11):1706-12.
  14. “British Cancer Association Consortium website.”
  15. “CHEK2 is a multiorgan cancer susceptibility gene.” Am J Human Genet 2004;75(6):1131-35.
  16. “C polymorphism in the P2×7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters.” J Clin Endocrinol Metab. 2009;94(2):695-98.
  17. “The delta 32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population.” Clin Biochem 2005;38(3):248-52.
  18. “Genome-wide association study identifies novel breast cancer susceptibility loci.” Nature 2007;447(7148):1087-93.
  19. “Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population.” J Endocrinol Invest 2007;30(5):411-16.
  20. “Interleukin- 10 gene polymorphism in patients with papillary thyroid cancer in Turkish population.” J Endocrinol Invest 2008;31(9):750-54.
  21. “Genomewide Association Studies and Assessment of the Risk of Disease.” New England Journal of Medicine 2010;363(2):166-76.
  22. “AACE/AAES Medical/Surgical guidelines for clinical practice: Management of Thyroid Carcinoma.” Endocrine Practice 2001;7(3):202-20.
  23. “Combined effects of glutathione S-transferase polymorphisms and thyroid cancer risk.” Cancer Genet Cytogenet 2004;151(1):60-67.
  24. “Globocan Statistics” 2008.
  25. “GST profiling may be useful in the screening for thyroid nodule malignancy.” Cancer Lett 2004;209(2):129-37.
  26. “Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer.” Cancer Lett 2004;210(2):151-57.
  27. “GSTO polymorphism analysis in thyroid nodules suggest that GSTO1 variants do not influence the risk for malignancy.” Eur J Cancer Prev 2005;14(3):277-80.
  28. “What makes a good genetic association study?” Lancet 2005;366:1315-23.
  29. “Glutathione S-transferase polymorphisms in thyroid cancer patients.” Cancer Lett 2003;190(1):37-44.
  30. “Role of GST and NAT2 polymorphisms in thyroid cancer.” J Endocrinol Invest 2008;31(11):1025-31.
  31. “Absence of allelic imbalance involving EMSY, CAPN5, and PAK1 genes in papillary thyroid carcinoma.” J Endocrinol Invest 2008;31(7):618-23.
  32. “Polymorphisms in the p53 gene in thyroid tumours and blood samples of children from areas in Belarus.” Mutat Res 1997;381(2):201-07.
  33. “Polymorphisms of xenobiotic-metabolising enzymes and susceptibility to cancer.” Env Health Perspective 107(1 Supplement): 1999;37-47.
  34. “RET polymorphisms and haplotypes and risk of differentiated thyroid cancer.” Laryngoscope 2005;115(6):1035-41.
  35. “Glutathione S-transferase polymorphisms and risk of differentiated thyroid carcinomas: A case-control analysis.” Arch Otolaryngol Head Neck Surg 2006;132(7):756-61.
  36. “Fas single nucleotide polymorphisms and risk of thyroid and salivary gland carcinomas: A case-control analysis.” Head Neck 2008;30(3):297-305.
  37. “Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: A casecontrol analysis.” Thyroid 2009;19(2):129-35.
  38. “Vascular endothelial growth factor gene polymorphisms in thyroid cancer.” J Endocrinol 2007;195(2):265-70.
  39. “Initial results from a prospective cohort study of 5583 cases of thryoid carcinoma treated in the United States during 1996.” Cancer 2000;89(1):202-17.
  40. “The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis.” Oncogene 2004;23(52):8432-38.
  41. ” Proc Natl Acad Sci USA. 2008;105(20):7269-74.
  42. “Well differentiated thyroid carcinoma is associated with human lymphocyte antigen D-related 11 in Eastern Hungarians: A case of changing circumstances.” Cancer 2005;104(8):1603-08.
  43. “Single nucleotide polymorphism seeking long term association with complex disease.” Nucleic Acids Research 2002;30(15):3295-3311.
  44. “The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors.” PLoS Genet 2009;5(9):e1000637.
  45. “Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.” Clin Endocrinol Oxf 2007;67(2):180-83.
  46. “Combined GSTM1 and GSTT1 null genotypes are associated with a lower risk of papillary thyroid cancer.” J Endocrinol Invest 2008;31(6):542-45.
  47. “Specific haplotypes of the RET proto-oncogene are overrepresented in patients with sporadic papillary thyroid carcinoma.” J Med Genet 2002;39(4):260-65.
  48. “Glutathione peroxidase 3 gene polymorphisms and risk of differentiated thyroid cancer.” Surgery 2009;145(5):508-13.
  49. “Strengthening the Reporting of Genetic Association Studies (STREGA)–An extension of the STROBE statement„ Genet Epidemiol 2009;33(7):581-98.
  50. “Papillary thyroid cancer and polymorphic variants in TSHR and RET-related genes: A nested case-control study within a cohort of US radiologic technologists.” Cancer Epidemiol Biomarkers Prev. 2007;16(1):174-77.
  51. “Association of polymorphisms in estrogen and thyroid hormone receptors with thyroid cancer risk.” J Recept Signal Transduct Res 2009;29(2):113-18.
  52. “Cancer Familial Aggregation (CFA) and G446A polymorphism in ARLTS1 gene.” Breast Cancer Res Treat 2006;99(1):59-62.
  53. “Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene.” Carcinogenesis 2004;25(3):369-73.
  54. , Cook, DJ, Eastwood, S, Olkin, I, Rennie, D, Stroup, DF. “Improving the Quality of Reports of Meta-Analyses of Randomised- Controlled Trials: The QUORUM Statement” Lancet 1999;354:1896-1900.
  55. “Does the quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?” Lancet 1998;352:609-13.
  56. “The null genotype of glutathione s-transferase M1 and T1 locus increases the risk for thyroid cancer.” Cancer Epidemiol Biomarkers Prev 2002;11(11):1485-88.
  57. “The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients.” J Endocrinol Invest 2009;32(6):491-94.
  58. “Global Cancer Statistics 2002.” CA Can J Clin 2005;55(2):74-108.
  59. “Vitamin D receptor polymorphisms in differentiated thyroid carcinoma.” Thyroid 2009;19(6): 623-28.
  60. “TP53 codon 72 polymorphism in radiationassociated human papillary thyroid cancer.” Oncol Rep 2006;15(4):949-56.
  61. “Obstacles and opportunities in metaanalysis of genetic association studies.” Genetics in Medicine 2005;7(1):13-20.
  62. For the CONSORT Group.’ “Consort Statement 2010 Statement: Updated guidelines for reporting parallel group randomised trials.” Ann Int Med 2010;152(EPub):24.
  63. “The C allele of the GNB3 C825T polymorphism of the G protein beta3-subunit is associated with an increased risk for the development of oncocytic thyroid tumours.” J Pathol 2007;211(1):60-66.
  64. “Thyroid nodules, polymorphic variants in DNA repair and RET-related genes, and interaction with ionizing radiation exposure from nuclear tests in Kazakhstan.” Radiat Res 2009;171(1):77-88.
  65. “Association of polymorphisms in ERCC2 gene with non-familial thyroid cancer risk.” Cancer Epidemiol Biomarkers Prev 2005; 2005;(14):10.
  66. “GSTT1 and M1 polymorphisms in Hürthle thyroid cancer patients.” Cancer Lett 2006;240(1):76-82.
  67. “Radiation response genotype and risk of differentiated thyroid cancer: A case-control analysis.” Laryngoscope 2005;115(6):938-45.
  68. “The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies” J Clin Epidemiol 2008;61(4):344-49.
  69. “Assessing the probability that a positive report is false: An approach for molecular epidemiology studies.” J Natl Cancer Institute 2004;96:434-42.
  70. “A range of cancers is associated with the rs6983267 marker on chromosome 8.” Cancer Res 2008;68(23):9982-86.
  71. “L-myc gene polymorphism and risk of thyroid cancer.” Exp Oncol 2008;30(2):117-20.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.